title: French field experience with buprenorphine.
abstract: In most European countries, methadone treatment is provided to only 20-30% of opiate abusers who need treatment due to regulations and concerns about safety. To address this need in France, all registered medical doctors since 1995 have been allowed to prescribe buprenorphine (BUP) without any special education or licensing. This led to treating approximately 65,000 patients per year with BUP, about ten times more than with more restrictive methadone policies. French physician compensation mechanisms, pharmacy services, and medical insurance funding all minimized barriers to BUP treatment. About 20% of all physicians in France are using BUP to treat about half of the estimated 150,000 problem heroin users. Daily supervised dosing by a pharmacist for the first six months resulted in significantly better treatment retention (80% vs 46%) and lower heroin use. Intravenous diversion of BUP may occur in up to 20% of BUP patients and has led to various infections and relatively rare overdoses in combination with sedatives. Opiate overdose deaths have declined substantially (by 79%) since BUP was introduced in 1995. Newborn opiate withdrawal in mothers treated with buprenorphine compared to methadone was reported to be less frequent, less severe, and of shorter duration. Although some of the public health benefits seen during the time of buprenorphine expansion in France might be contingent upon characteristics of the French health and social services system, the French model raises questions about the value of tight regulations on prescribing BUP imposed by many countries throughout the world.
authors.affiliation: Department of Psychiatry and Addiction, Victor Pachon Medical School, Université Victor Segalen Bordeaux 2, Bordeaux, France. marc.auriacombe@labopsy.u-bordeaux2.fr
authors.forename: Marc
authors.initials: M
authors.lastname: Auriacombe
authors.forename: Mélina
authors.initials: M
authors.lastname: Fatséas
authors.forename: Jacques
authors.initials: J
authors.lastname: Dubernet
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Daulouède
authors.forename: Jean
authors.initials: J
authors.lastname: Tignol
mesh_terms: D000328:Adult; D002047:Buprenorphine / Q000627:therapeutic use*; D002423:Cause of Death / Q000639:trends; D003431:Cross-Cultural Comparison; D017277:Drug Approval / Q000331:legislation & jurisprudence; D062787:Drug Overdose / Q000401:mortality / Q000517:prevention & control; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005544:Forecasting; D005602:France; D006297:Health Services Accessibility / Q000639:trends; D006556:Heroin Dependence / Q000401:mortality / Q000534:rehabilitation; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008691:Methadone / Q000627:therapeutic use; D009294:Narcotics / Q000627:therapeutic use*; D009357:Neonatal Abstinence Syndrome / Q000401:mortality / Q000517:prevention & control; D009293:Opioid-Related Disorders / Q000401:mortality / Q000534:rehabilitation*; D011247:Pregnancy
chemical_list: D009294:Narcotics; D002047:Buprenorphine; D008691:Methadone